FDG PET/CT predictive role in follicular lymphoma
- PMID: 22354449
- DOI: 10.1007/s00259-012-2079-y
FDG PET/CT predictive role in follicular lymphoma
Abstract
Purpose: We present findings concerning (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) at end-treatment evaluation in follicular lymphoma (FL) in order to establish possible predictive factors for progression-free survival (PFS) and patient outcome.
Methods: We retrospectively analysed data from 91 consecutive FL patients (M:F = 51:40, mean age 61) referred to our PET Unit at therapy completion: 38 with an indolent form (grade 1-2) and 53 with an aggressive FL (grade 3a and b) according to the World Health Organization (WHO) classification. A total of 148 FDG PET/CT scans were analysed and findings reported as positive or negative for disease. The overall response to treatment was assessed according to the revised International Workshop Criteria (IWC). The final outcome was defined as remission or disease by taking clinical, instrumental and histological data as standards of reference, with a mean follow-up period of 3 years (range 1-8). A statistical analysis was performed with respect to PFS and patient outcome for FDG PET result, tumour grading, Follicular Lymphoma International Prognostic Index (FLIPI), disease stage and number of relapses, on uni- and multivariate analyses, with p < 0.05 considered as significant.
Results: Overall patients presented a mean PFS of 35 months (range 3-86), with a relapse rate of 42%. At final outcome, remission was achieved in 67 of 91 patients (74%). Of the different predictive factors, only FDG PET result significantly correlated with patient outcome (p = 0.0002). PET/CT performance at the end of treatment was as follows: 100% sensitivity, 99% specificity, 89% positive predictive value and 100% negative predictive value. The Kaplan-Meier analysis demonstrated a statistically significant correlation with PFS for FDG PET (p < 0.0001), FLIPI score (0-1 versus ≥ 2) (p = 0.0451) and number of relapses (none versus ≥ 1) (p = 0.0058). These findings were confirmed at the univariate analysis, whereas at the multivariate analysis only FDG PET (p = 0.0006892) and number of relapses (p = 0.01947) were independent predictive factors for PFS.
Conclusion: End-treatment PET/CT in FL has high accuracy and appears to be a good predictor of PFS and patient outcome, irrespective of grading. As expected, patients facing more than one relapse seem to have significantly shorter PFS in the presence of a positive FDG PET.
Similar articles
-
The prognostic value of mid- and post-treatment [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma.Ann Nucl Med. 2014 Oct;28(8):805-11. doi: 10.1007/s12149-014-0874-1. Epub 2014 Jul 10. Ann Nucl Med. 2014. PMID: 25008291
-
FDG-PET/CT at the end of immuno-chemotherapy in follicular lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET).Ann Nucl Med. 2018 Jun;32(5):372-377. doi: 10.1007/s12149-018-1243-2. Epub 2018 Feb 20. Ann Nucl Med. 2018. PMID: 29464479
-
End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial.Eur J Nucl Med Mol Imaging. 2024 Sep;51(11):3311-3321. doi: 10.1007/s00259-024-06765-z. Epub 2024 May 25. Eur J Nucl Med Mol Imaging. 2024. PMID: 38795120 Clinical Trial.
-
Impact of (18)F-FDG PET/CT on the staging and management of follicular lymphoma.Br J Radiol. 2014 Oct;87(1042):20140360. doi: 10.1259/bjr.20140360. Epub 2014 Jul 25. Br J Radiol. 2014. PMID: 25061910 Free PMC article. Review.
-
Follicular Lymphoma Treated with First-Line Immunochemotherapy: A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM Study.J Nucl Med. 2022 Aug;63(8):1149-1154. doi: 10.2967/jnumed.121.262869. Epub 2021 Dec 2. J Nucl Med. 2022. PMID: 34857656 Free PMC article. Review.
Cited by
-
Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma.Ther Adv Hematol. 2013 Jun;4(3):189-98. doi: 10.1177/2040620713480522. Ther Adv Hematol. 2013. PMID: 23730496 Free PMC article.
-
Does tumoral (111)In-ibritumomab accumulation correlate with therapeutic effect and outcome in relapsed or refractory low-grade B-cell lymphoma patients undergoing (90)Y-ibritumomab radioimmunotherapy?Eur Radiol. 2014 Dec;24(12):3191-8. doi: 10.1007/s00330-014-3378-4. Epub 2014 Aug 12. Eur Radiol. 2014. PMID: 25117746
-
Tumor long-axis diameter and SUVmax predict long-term responders in 90Y-ibritumomab tiuxetan monotherapy.Int J Hematol. 2019 Jan;109(1):91-97. doi: 10.1007/s12185-018-2526-z. Epub 2018 Sep 10. Int J Hematol. 2019. PMID: 30203253
-
Diagnostic role of 18F-fluorodeoxyglucose positron emission tomography for follicular lymphoma with gastrointestinal involvement.World J Gastroenterol. 2012 Nov 28;18(44):6427-36; discussion p.6434. doi: 10.3748/wjg.v18.i44.6427. World J Gastroenterol. 2012. PMID: 23197888 Free PMC article.
-
Predictive Value of Interim and End-of-Therapy 18F-FDG PET/CT in Patients with Follicular Lymphoma.Nucl Med Mol Imaging. 2019 Aug;53(4):263-269. doi: 10.1007/s13139-019-00602-0. Epub 2019 Jun 29. Nucl Med Mol Imaging. 2019. PMID: 31456859 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials